[go: up one dir, main page]

WO2001032871A3 - Follistatin-related protein zfsta4 - Google Patents

Follistatin-related protein zfsta4 Download PDF

Info

Publication number
WO2001032871A3
WO2001032871A3 PCT/US2000/030013 US0030013W WO0132871A3 WO 2001032871 A3 WO2001032871 A3 WO 2001032871A3 US 0030013 W US0030013 W US 0030013W WO 0132871 A3 WO0132871 A3 WO 0132871A3
Authority
WO
WIPO (PCT)
Prior art keywords
zfsta4
follistatin
related protein
polypeptides
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/030013
Other languages
French (fr)
Other versions
WO2001032871A2 (en
Inventor
Darrell C Conklin
Paul O Sheppard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Priority to AU13564/01A priority Critical patent/AU1356401A/en
Priority to JP2001535553A priority patent/JP2003527099A/en
Priority to EP00975521A priority patent/EP1226249A2/en
Priority to CA002389956A priority patent/CA2389956A1/en
Publication of WO2001032871A2 publication Critical patent/WO2001032871A2/en
Publication of WO2001032871A3 publication Critical patent/WO2001032871A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to polynucleotide and polypeptide molecules for zfsta4, a novel member of the follistatin family. The polypeptides, and polynucleotides encoding them are useful for binding to members of the TGF-β family and mediating central nervous system, reproductive, hematopoietic and bone-related activities. The present invention also includes antibodies to the zfsta4 polypeptides.
PCT/US2000/030013 1999-11-03 2000-10-31 Follistatin-related protein zfsta4 Ceased WO2001032871A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU13564/01A AU1356401A (en) 1999-11-03 2000-10-31 Follistatin-related protein zfsta4
JP2001535553A JP2003527099A (en) 1999-11-03 2000-10-31 Follistatin-related protein ZFSTA4
EP00975521A EP1226249A2 (en) 1999-11-03 2000-10-31 Follistatin-related protein zfsta4
CA002389956A CA2389956A1 (en) 1999-11-03 2000-10-31 Follistatin-related protein zfsta4

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43235999A 1999-11-03 1999-11-03
US09/432,359 1999-11-03

Publications (2)

Publication Number Publication Date
WO2001032871A2 WO2001032871A2 (en) 2001-05-10
WO2001032871A3 true WO2001032871A3 (en) 2002-02-21

Family

ID=23715814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030013 Ceased WO2001032871A2 (en) 1999-11-03 2000-10-31 Follistatin-related protein zfsta4

Country Status (5)

Country Link
EP (1) EP1226249A2 (en)
JP (1) JP2003527099A (en)
AU (1) AU1356401A (en)
CA (1) CA2389956A1 (en)
WO (1) WO2001032871A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050075283A1 (en) * 2001-07-13 2005-04-07 Applera Corporation Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
MXPA04008149A (en) * 2002-02-21 2005-06-17 Wyeth Corp Follistatin domain containing proteins.
JP4688483B2 (en) * 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 Follistatin variant polypeptide
CA2566257A1 (en) * 2004-05-07 2005-11-24 Applera Corporation Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof
WO2008002661A2 (en) * 2006-06-28 2008-01-03 The Board Of Trustees Of The Leland Stanford Junior University Fusion protein constructs
WO2008002663A2 (en) 2006-06-28 2008-01-03 The Board Of Trustees Of The Leland Stanford Junior University Immunogenic protein constructs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054358A1 (en) * 1997-05-26 1998-12-03 Monash University A method of diagnosing abnormal cell growth
WO1999025371A1 (en) * 1997-11-17 1999-05-27 Millennium Pharmaceuticals, Inc. Novel molecules of the follistatin-related protein family and uses therefor
WO2000061754A2 (en) * 1999-04-09 2000-10-19 Curagen Corporation Human proteins and polynucleotides encoding them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054358A1 (en) * 1997-05-26 1998-12-03 Monash University A method of diagnosing abnormal cell growth
WO1999025371A1 (en) * 1997-11-17 1999-05-27 Millennium Pharmaceuticals, Inc. Novel molecules of the follistatin-related protein family and uses therefor
WO2000061754A2 (en) * 1999-04-09 2000-10-19 Curagen Corporation Human proteins and polynucleotides encoding them

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EM_HTG EMBL; 17 September 1999 (1999-09-17), DOE JOINT GENOME INSTITUTE: "Homo sapiens chromosome 5 clone CTB-49A3, WORKING DRAFT SEQUENCE, 53 unordered pieces.", XP002172088 *
DATABASE EM_HTG EMBL; 4 August 1999 (1999-08-04), DOE JOINT GENOME INSTITUTE: "Homo sapiens chromosome 5 clone CTC-439D5, WORKING DRAFT SEQUENCE, 19 unordered pieces.", XP002172087 *
DATABASE EM_HUM EMBL; 30 June 1998 (1998-06-30), KIMMERLY W ET AL.: "Homo sapiens chromosome 5, P1 clone 1265G12 (LBNL H58), complete sequence.", XP002172086 *
DATABASE EM_HUM EMBL; 4 August 1999 (1999-08-04), OHARA O ET AL.: "Homo sapiens mRNA for KIAA1061 protein, partial cds.", XP002172085 *
KIKUNO R ET AL.: "Prediction of the coding sequences of unidentified human genes. XIV. The complete sequences of 100 new cDNA clones from brain which encod for large proteins in vitro", DNA RESEARCH, vol. 6, no. 3, 30 June 1999 (1999-06-30), pages 197 - 205, XP000852618 *
TANAKA M ET AL.: "Cloning of follistatin-related protein as a novel autoantigen in systemic rheumatic diseases", INTERNATIONAL IMMUNOLOGY, vol. 10, no. 9, 1998, pages 1305 - 1314, XP000945149, ISSN: 0953-8178 *
ZWIJSEN A ET AL.: "Characterization of a rat C6 glioma-secreted follistatin-related protein (FRP);cloning and sequencing of the human homologue", EUROPEAN JOURNAL OF BIOCHEMISTRYEUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 225, no. 3, November 1994 (1994-11-01), pages 937 - 946, XP002103181, ISSN: 0014-2956 *

Also Published As

Publication number Publication date
AU1356401A (en) 2001-05-14
CA2389956A1 (en) 2001-02-10
JP2003527099A (en) 2003-09-16
EP1226249A2 (en) 2002-07-31
WO2001032871A2 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
EP1482040A3 (en) Nl3 tie receptor tyrosine kinase ligand homologues
EP0832973A3 (en) GTP-binding protein
CA2200423A1 (en) Novel estrogen receptor
IE901696L (en) Fibronectin binding protein as well as its preparation
WO1999015653A3 (en) Tie ligand homologues
DE69832178D1 (en) TRAIL BINDING RECEPTOR
CA2135208A1 (en) Immunoglobulin binding proteins derived from l protein and their uses
WO2002038592A3 (en) Peptides, the production and use thereof for binding immunoglobulins
EP0913476A3 (en) Ornithine carbamoyl transferase sequence and uses thereof
CA2302147A1 (en) Methods for protein screening
WO2001032871A3 (en) Follistatin-related protein zfsta4
IL134577A0 (en) Rtd receptor
WO1997044451A3 (en) Vasoactive amine binding molecules
EP0832978A3 (en) Novel 3-dehydroquinate synthase
EP0897011A3 (en) Novel arginine deiminase
EP0892064A3 (en) Recombinant secA2 polypeptide from Staphylococcus aureus and uses thereof
WO2004090103A3 (en) Identification of novel nogo-receptors and methods related thereto
EP0911409A3 (en) Deformylase
EP0900845A3 (en) Signal recognition particle polypeptides and polynucleotides
EP0885965A3 (en) Histidine kinase polypeptides
EP0892059A3 (en) Histidine kinase polypeptides
EP0909820A3 (en) Histidine kinase from Staphylococcus pneumoniae
EP0885963A3 (en) Compounds comprising polypeptides and polynucleotides of Streptococcus pneumoniae,said polypeptides being related by amino acid sequence homology to SapR from Streptococcus mutans polypeptide
EP0885966A3 (en) Novel compouds
EP0900844A3 (en) Membrane protein of Staphylococcus aureus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2389956

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000975521

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 535553

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000975521

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000975521

Country of ref document: EP